AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
ASTRAZENECA PHARMA | DIVIS LABORATORIES | ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 113.7 | 48.1 | 236.3% | View Chart |
P/BV | x | 34.8 | 12.9 | 270.5% | View Chart |
Dividend Yield | % | 0.0 | 0.5 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
DIVIS LABORATORIES Mar-19 |
ASTRAZENECA PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 1,639 | 78.0% | |
Low | Rs | 883 | 1,115 | 79.2% | |
Sales per share (Unadj.) | Rs | 228.4 | 186.3 | 122.6% | |
Earnings per share (Unadj.) | Rs | 10.4 | 51.0 | 20.3% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 57.3 | 28.4% | |
Dividends per share (Unadj.) | Rs | 0 | 16.00 | 0.0% | |
Dividend yield (eoy) | % | 0 | 1.2 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 261.8 | 37.7% | |
Shares outstanding (eoy) | m | 25.00 | 265.47 | 9.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 7.4 | 64.0% | |
Avg P/E ratio | x | 104.2 | 27.0 | 385.7% | |
P/CF ratio (eoy) | x | 66.4 | 24.0 | 276.5% | |
Price / Book Value ratio | x | 10.9 | 5.3 | 207.9% | |
Dividend payout | % | 0 | 31.4 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 365,592 | 7.4% | |
No. of employees | `000 | 1.4 | 11.8 | 11.4% | |
Total wages/salary | Rs m | 1,535 | 5,423 | 28.3% | |
Avg. sales/employee | Rs Th | 4,210.9 | 4,175.1 | 100.9% | |
Avg. wages/employee | Rs Th | 1,132.2 | 457.7 | 247.4% | |
Avg. net profit/employee | Rs Th | 191.1 | 1,141.8 | 16.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 49,463 | 11.5% | |
Other income | Rs m | 123 | 1,556 | 7.9% | |
Total revenues | Rs m | 5,833 | 51,019 | 11.4% | |
Gross profit | Rs m | 463 | 18,718 | 2.5% | |
Depreciation | Rs m | 147 | 1,689 | 8.7% | |
Interest | Rs m | 0 | 35 | 0.0% | |
Profit before tax | Rs m | 438 | 18,551 | 2.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 5,023 | 3.6% | |
Profit after tax | Rs m | 259 | 13,527 | 1.9% | |
Gross profit margin | % | 8.1 | 37.8 | 21.4% | |
Effective tax rate | % | 40.8 | 27.1 | 150.8% | |
Net profit margin | % | 4.5 | 27.3 | 16.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 46,501 | 6.9% | |
Current liabilities | Rs m | 2,070 | 8,468 | 24.4% | |
Net working cap to sales | % | 20.0 | 76.9 | 26.0% | |
Current ratio | x | 1.6 | 5.5 | 28.2% | |
Inventory Days | Days | 72 | 131 | 55.3% | |
Debtors Days | Days | 35 | 86 | 40.7% | |
Net fixed assets | Rs m | 790 | 25,797 | 3.1% | |
Share capital | Rs m | 50 | 531 | 9.4% | |
"Free" reserves | Rs m | 2,419 | 68,962 | 3.5% | |
Net worth | Rs m | 2,469 | 69,493 | 3.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 4,605 | 80,383 | 5.7% | |
Interest coverage | x | NM | 531.0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.2 | 0.6 | 201.5% | |
Return on assets | % | 5.6 | 16.9 | 33.3% | |
Return on equity | % | 10.5 | 19.5 | 53.9% | |
Return on capital | % | 17.7 | 26.7 | 66.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 24.6 | 0.0% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | 12,187 | 0.0% | |
Fx inflow | Rs m | 300 | 41,238 | 0.7% | |
Fx outflow | Rs m | 2,015 | 12,405 | 16.2% | |
Net fx | Rs m | -1,715 | 28,833 | -5.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 9,543 | 0.9% | |
From Investments | Rs m | -94 | -6,854 | 1.4% | |
From Financial Activity | Rs m | NA | -2,459 | 0.0% | |
Net Cashflow | Rs m | -6 | 230 | -2.5% |
Indian Promoters | % | 0.0 | 52.0 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.3 | 11.8 | 2.5% | |
FIIs | % | 15.7 | 19.0 | 82.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 17.2 | 52.9% | |
Shareholders | 12,856 | 31,796 | 40.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: PIRAMAL ENTERPRISES NOVARTIS PANACEA BIOTECH DR. REDDYS LAB GSK PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed a sharp sell-off today and ended deep in the red.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More